SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15–19, 2014, in Boston, Massachusetts.
| |||||
“Vectra DA is a game changer for patients with RA because it provides clinical insights that help inform and improve clinical decisions for patients more effectively than tests like CRP or ESR,” said Oscar Segurado, M.D., Chief Medical Officer of Crescendo. “The new clinical data being presented at ACR support the use of Vectra DA to assess RA disease activity and predict patient risk of joint damage.”
| Oral Presentations | |
| Title: | The multi-biomarker disease activity score as a predictor of radiographic progression in a registry of patients with rheumatoid arthritis. |
| Presenter: | Eric H. Sasso |
| Date: | November 19, 2014 9:30 a.m., Room 258 B, Presentation Number 2973 |
| Title: | Multi-biomarker disease activity score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state. |
| Presenter: | Nadine Defranoux |
| Date: | November 19, 2014 9:45 a.m., Room 258 B, Presentation Number 2974 |
| Poster Presentations | |
| Title: | Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment. |
| Presenter: | Ronald F. van Vollenhoven |
| Date: | November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 376 |
| Title: | In early rheumatoid arthritis, the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression. |
| Presenter: | Karen Hambardzumyan, |
| Date: | November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 364 |
| Title: | In early rheumatoid arthritis patients with non-response to methotrexate monotherapy the change in multi-biomarker disease activity score is differentially associated with subsequent response to non-biological versus biological therapy. |
| Presenter: | Karen Hambardzumyan |
| Date: | November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 367 |
| Title: | Preliminary assessment of a multi-biomarker disease activity test for axial spondyloarthritis. |
| Presenter: | Walter P. Maksymowych |
| Date: | November 18, 2014, 9:00-11:00 a.m. Exhibit Hall B, Presentation Number 2615 |
About Vectra DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit, www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, California. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at: www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad’s molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual’s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Vectra clinical study data to be presented at the 2014 American College of Rheumatology (ACR) Annual Meeting, November 15-19, 2014, in Boston, Massachusetts; the significant clinical value of Vectra DA, which may help doctors manage patients based on their risk of disease progression; the effectiveness of Vectra DA testing to objectively predict disease progression in patients newly diagnosed with rheumatoid arthritis (RA); and the Company’s strategic directives under the captions “About Vectra DA,” “About Crescendo Bioscience” and “About Myriad Genetics.” These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
CONTACT: Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com
Help employers find you! Check out all the jobs and post your resume.
